Rashidan Shah Abdul Rahim
To Allah we belong, and to Him we return - Al-fatihah
b.1965 - d 27th October 2014
Remembering a cherished colleague and companion,
and a loving husband of 18 years and father of two children.
Rashidan Shah is an Investments Director for Xeraya Capital after joining the company on 2nd May 2012 until his untimely demise on the 27th October 2014. He has more than 20 years of experience in the field of investment both in public equities and venture capital following his graduation in 1989. His career has taken him from an investment analyst in a fund management subsidiary of Permodalan Nasional Berhad, through various securities firms namely UMBC Securities, Charles Bradburne Securities, Capital Corp Securities, Smith Zain Securities and BBMB Securities as investment analyst, institutional sales person and later as head of research, specialising in the banking and power sectors and market strategy.
In 2002, he was promoted as the Executive Director of Dealing of BBMB Securities and Corporate Nominee on the Kuala Lumpur Stock Exchange (KLSE) representing his Company which was a member company of the KLSE. With a team of approximately 30 dealers and 200 remisiers, he headed the sales team to become one of the top 5 stockbroking firms in the country.
In 2004, he joined Malaysian Technology Development Corporation as an Assistant General Manager for Investments and led the investment work on various Life Sciences and non-Life Sciences companies. He was also involved in the preparation of Malaysia's Biotechnology Plan which led to the setting up of Malaysian Biotech Corporation in 2005.
Rashidan was also involved in the groundwork and setting up of the Malaysian Life Sciences Capital Fund I which was incorporated in late 2006 and from then onwards utilised half of his time as part of the management team in MLSCF. He was also involved as an investment committee member and played an instrumental role in making some of the fund's investments and was a key member for many of MLSCF's investee companies.
In 2009, while still in MTDC, he was promoted as a Director for MLSCF and Special Projects, and led the MTDC team to organise the inaugural and highly successful Kuala Lumpur Venture Capital Symposium in 2011.
Aditya Puri is an Investment Partner at Xeraya Capital; he joined the company in October 2012.
Previously, he was a Director in Khazanah Nasional's Life Sciences unit, which was responsible for Khazanah's Life Sciences investments. He has almost 20 years of experience and leadership in new ventures, corporate investing, and international expansion in life science and technology industries.
Prior to Khazanah, Aditya was in the greater Boston area working with Healthcare and Cleantech startups affiliated with Harvard and MIT. He evaluated new technologies and partnered with inventors at high potential startups, and consulted on growth, customer acquisition, and commercialization strategies. He was also part of the leadership team at Yankee Group, a global technology research and consulting company, where he launched and had full P&L responsibility for a multimillion dollar global licensing and subscription business. He joined them as a consultant covering Asia Pacific, and advised clients on market entry, due diligence, and investment related decisions.
At Boston Scientific, a Fortune 500 medical device manufacturer, Aditya was part of a five-member team reporting to the CFO chartered with the company's inorganic growth and corporate development activity. In this role he identified and closed new investment opportunities, and was instrumental in deals that have, in addition to high returns, resulted in significant long-term value for the company. He began his career at KPMG.
Aditya has a B.S. from the University of Southern Maine, graduating Summa Cum Laude, and received his MBA from the MIT Sloan School of Management. He has also passed all parts of the U.S. Uniform CPA Examination.
Jason brings with him a wealth of life science experience with strong business networks especially in Europe. He is an accomplished life sciences practitioner with over two decades of experience in various areas in the sector including drug development, drug discovery, management consulting, venture capital, strategy consulting and corporate finance advisory.
Jason joined Xeraya Capital from Deloitte, Geneva, Switzerland where for five years he was Director, Corporate Finance Advisory, leading the firm's healthcare and life science advisory (M&A) business. Before joining Deloitte he spent a short period as a independent strategy consultant.
His working career in the venture capital industry began with the Merlin Biosciences Fund and later with the Inventages (Nestle) Fund where he sourced, evaluated and closed numerous venture capital investments and was involved in post investment management of portfolio companies including taking on Board positions. Prior to that Jason was a management consultant in the life science group of PA Consulting. His early career was in the sciences, initially in drug development with Medeva Group and Cortecs Ltd, and later in drug discovery with Eli Lilly.
Jason holds a Master of Science degree in Immunology, and a Bachelor of a Science (Hons) degree in Anatomy, both from the University of Birmingham, UK.
Lim Su San
Investments Senior Vice President
Susan joined Xeraya Capital as an Investments Senior Vice President in October 2012. She was previously SVP at Khazanah Research & Investment Strategy (KRIS)'s Life Sciences Unit, which formulates investment strategies, and undertakes and monitors the organisation's Life Sciences investments.
As part of the Life Sciences Unit's founding team, Susan was a key element in the various achievements of the group. She has been deeply involved in all the direct and indirect investments, and at various times has led or managed critical facets of the investment process - opportunity assessment, valuation, selection and oversight of external advisors - to name a few. She is also credited with streamlining the various internal processes to consummate investments at Khazanah, including building the framework and relationships with all the necessary constituents. One of her primary ongoing responsibilities includes the performance monitoring of the Life Sciences Unit's global investment portfolio.
Susan has more than 10 years of experience in the finance and investment fields. She joined Khazanah in September 2005 from Malaysian Rating Corporation Berhad (MARC), where she was a member of the Internal Rating Committee. The group was responsible for ratings related to project finance and corporate debts in various sectors, including infrastructure, conglomerates, utilities, and oil and gas related companies. Prior to joining MARC, she was a Credit Review Officer at AmMerchant Bank Berhad.
Susan holds a Bachelor of Business degree, with a major in Economics and Finance, from RMIT University, Melbourne, Australia. She is also a Chartered Financial Analyst (CFA) charterholder.
Norazli bin Mohamad Nor
Investments Senior Vice President
Norazli bin Mohamad Nor joined Xeraya Capital as a Vice President from Khazanah in October 2012. He has over 17 years of career experience that includes investment, consulting and execution. He has expertise in corporate strategies, finance and operations with a delivery record relating to acquisition, restructuring, operational turnaround and large-scale engineering delivery.
In 2008, Norazli joined Khazanah Nasional as a Vice President. In that role, he has assessed investment pipeline deals and startups, whilst overseeing a portfolio comprising of over 20 technology companies. He was deeply involved in the preparatory aspects and the inception of both Xeraya Capital and the Mudharabah Innovation Fund.
Before Khazanah, Norazli was an Associate Director at KPMG's consulting practice, focusing primarily in infrastructure development, particularly public-private partnerships and private finance initiatives. Between 1995 and 2007 he worked at Tenaga Nasional Berhad in various technical and management consulting leadership roles.
He was registered as a Professional Engineer with the Board of Engineers Malaysia. Azli holds a Bachelor of Engineering (Electrical and Electronics) from Imperial College, London, United Kingdom, and an MBA in Finance from International Islamic University Malaysia.
Goh Wei Ling
Investments Vice President
Wei Ling joined Xeraya in December 2013 as VP, Investments. She carries with her over 10 years of private equity experience, which included frontline investment work, fund management and fund raising activities. Wei Ling also brings to Xeraya extensive experience in conducting corporate due diligence, deal execution, portfolio monitoring including sitting on Boards of investee companies and stakeholder management. She was previously with CDC Group plc and Actis Capital (following the de-merger from CDC) working as the Accountant based in Malaysia. She subsequently moved on to doing full time investment with Aureos Capital/The Abraaj Group.
She started her career with KPMG as an auditor. She was also involved in financial due diligence assignments and corporate restructuring exercises.
Wei Ling is an Australian CPA and a Malaysian Chartered Accountant. She holds a Bachelor of Business (Accountancy) degree with distinction from RMIT University Australia.
Rohit Pratap Singh
Investments Assistant Vice President
Rohit joined Xeraya Capital as an Assistant Vice President in August 2015. He has over 10 years of career experience that includes investment banking and VC investments.
Rohit has extensive experience in the M&A/ VC space. As an investment banker, he has represented clients from Asia, Europe and USA in advising them in cross border acquisitions worth > USD 1 bn and as a VC he has been part of investments in U.S and Asia. Apart from developing skill sets in equity transactions, Rohit also brings in a cross cultural work experience gained working in different regions, jurisdictions, understanding of local/ international M&A laws and developing an extensive network of bankers and fund managers.
Prior to Xeraya, Rohit has worked in PwC, KPMG and Rabobank in their respective M&A/ Corporate Finance transaction teams. Rohit graduated as an engineer and has an MBA from India’s leading institution- Indian Institute of Technology, Kharagpur. He is also a Chartered Financial Analyst (“CFA”) charterholder.
Noorhayati M. Nasir
Investments Assistant Vice President
Noorhayati M. Nasir joined Xeraya Capital as an Assistant Vice President Investments in August 2016. Prior to Xeraya, she was Vice President Business Development and Investment Healthcare at Malaysian Biotechnology Corporation Sdn Bhd (BiotechCorp).
Noorhayati has 10 years of experience working on investments in Life Science specifically Healthcare sector, with primary concerns on economic development initiatives. She was responsible in assessing business proposals for grant and incentive applications, advising and facilitating investors in due diligence, business model structuring, business matching, government relations and project implementation. As part of the pioneer team in Healthcare Business Development and Investment unit, she successfully supported multiple investments into Malaysia in various subsectors under Healthcare.
Noorhayati was heavily involved in creating linkages between international companies and local universities to promote industry-academia partnership, fostering innovation and commercialization.
Whilst at BiotechCorp, Noorhayati was part of various policy development roundtable discussions and was appointed as the Core Team Member for the Horizon Scanning Committee under the Health Technology Assessment Unit in Ministry of Health (MOH) Malaysia, offering technical advise on new and emerging health technologies.
Noorhayati holds a Bachelor of Science Degree majoring in Biotechnology from University Malaya and an MBA in International Business from University Putra Malaysia.
Shafini Abd Hapiz
Shafini Abd Hapiz joined Xeraya Capital as an Associate, Investments in October 2012. Shafini has a diverse background in biotechnology and business. Before Xeraya, Shafini was an analyst intern in the corporate finance and investment banking group for Deutsche Bank in Singapore and London. In that role, she specialized in the chemical industry, developing and mining financial data to forecast revenue, and identifying future trends and risks. She was integral in the due diligence of several chemical companies in preparation for M&A and public offerings.
Before Deutsche Bank, she was a business development trainee at CellFacts Instruments Ltd in the UK. She developed market research and analysis on possible new industries for the firm to enter and worked with senior management on improving the company's sales and marketing execution. Previously, she was a patent executive trainee at Patrick Mirandah & Co. Bhd in Kuala Lumpur and held a summer internship at Environmental Biotechnology CRC in Sydney, Australia.
Shafini holds a Bachelor of Science degree (with first-class honours) in biotechnology from the University of New South Wales in Australia, and a Master of Science degree (with distinction) in biotechnology, bioprocessing and business management from the University of Warwick in the UK.
Siti Zafirah Bt Azmi
Zafirah Azmi joined us as an Associate, Investments for Xeraya Capital in January 2013. Previously, she had a business internship at Khazanah Nasional, where she focused on research and investment strategy. Zafirah graduated from the Universiti of Malaya with a Master of Science in Research (Plant Biotechnology) and has a Bachelor (Hons) in Industrial Biotechnology from the Universiti Selangor, where she was on the Dean's List.
In 2011, Zafirah was chosen to present a paper at the International Society for Horticultural Science In vitro & Horticultural Breeding Symposium in Ghent, Belgium. In addition, she was a delegate to Youth Defined: Shape Our Future Program National Level conference in 2011 and the Biomalaysia conference in 2010 and 2011. In 2012, she was author of two ISI-cited papers published on Punica granatum.
Nor Na'illah Bt Ahmad Satar
Na'illah Satar joined Xeraya as an Analyst in January 2015. After graduation, she had a one-year working experience at Khazanah Nasional as an Investment Trainee. She deals primarily with fund management in Africa, greenfield real estate projects, research and financial analysis of investment opportunities in Wellness and various sectors, both locally and abroad.
She also has previous short working stints in Halal food safety, pharmaceuticals and Organizational Development programs.
Na'illah graduated from the Pennsylvania State University in May 2013, with a BSc in Biotechnology, and minors in Business, Liberal Arts and Microbiology. She completed the International Baccalaureate ("IB") Diploma Program in May 2009.
Megat Khairul Ismail
Megat Khairul joined Xeraya Capital as an Investments Analyst in May 2015.
Prior to Xeraya Capital, he spent over 3 years in corporate finance and investment banking. He was most recently a Senior Analyst at Maybank Investment Bank Berhad where he was involved in the execution and financial due diligence of various corporate exercises, which include Initial Public Offerings, Acquisitions, Disposals and Privatisations.
He started his career with ECM Libra Investment Bank as an Investment Banking Analyst and was involved in deal originations in the equity and debt markets along with placements exercises of public listed entities in Malaysia.
Megat Khairul holds a Bachelor of Science degree (Hons) in Finance and Investment Banking from the University of Reading, United Kingdom.
Adrian joined Xeraya Capital as an Investment Analyst in July 2016. Before Xeraya Capital, Adrian was attached to Maybank Investment Bank for over two and a half years, where he was involved in the origination, structuring and execution of various investment banking and corporate finance mandates covering, amongst others, initial public offerings, mergers & acquisitions, corporate restructurings and independent dvisory services.
Prior to joining the investment banking industry, Adrian has over a year of private/ venture equity experience in Westhill Equity, which included experience in investment and financial appraisals, due diligence, preparation of periodic investment reports as well as portfolio monitoring and management.
Adrian holds a Bachelor of Science degree (with first-class honours) in Accounting and Finance from Lancaster University, United Kingdom. He is currently pursuing his ACCA qualifications.